

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

RSK1/RSK2/RSK3 Antibody

RRID:AB_330803

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9347, RRID:AB_330803

Antibody Information

URL: http://antibodyregistry.org/AB_330803

Proper Citation: Cell Signaling Technology Cat# 9347, RRID:AB_330803

Target Antigen: RSK1/RSK2/RSK3

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation on 11/2018: AB_10694805, AB_330803.

Antibody Name: RSK1/RSK2/RSK3 Antibody

Description: This polyclonal targets RSK1/RSK2/RSK3

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_330803

Vendor: Cell Signaling Technology

Catalog Number: 9347

Record Creation Time: 20250820T005029+0000

Record Last Update: 20250820T092027+0000

Ratings and Alerts

No rating or validation information has been found for RSK1/RSK2/RSK3 Antibody.

No alerts have been found for RSK1/RSK2/RSK3 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chatterjee D, et al. (2025) KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance. Molecular cancer research : MCR, 23(6), 553.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy, 25(1), 2332000.

Hicks HM, et al. (2021) Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Molecular carcinogenesis, 60(3), 201.

Ng PK, et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer cell, 33(3), 450.